Clinical trial · Interventional
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer
NCT00732563CI-TRIAL-00029951completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 works in detecting lymph node metastasis in patients with stage I or stage II non-small cell lung cancer that can be removed by surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy | Drug | Chemotherapy | ALIAS |
| fludeoxyglucose F 18 | Radiation | — | UNRESOLVED |
| lymphadenectomy | Procedure | — | UNRESOLVED |
| neoadjuvant therapy | Procedure | — | UNRESOLVED |
| quality-of-life assessment | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
| therapeutic conventional surgery | Procedure | — | UNRESOLVED |
| thoracic surgical procedure | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Survival rate at 2 years
- timeFrame
- 2 years
- measure
- Recurrence rate at 2 years
- timeFrame
- 2 years
Secondary outcomes (4)
- measure
- Positive threshold of lymph node radioactivity
- timeFrame
- within 90 days
- measure
- Comparison of the accuracy of detecting thoracic lymph node metastases using PET-CT scans versus intra-operative hand-held gamma probe
- timeFrame
- Within 90 days
- measure
- Ability of the gamma probe to detect lymph node micrometastases, resulting in upstaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of non-small cell lung cancer * Stage I-II disease * Resectable disease * Planning to undergo surgical resection * No tumors that are not fludeoxyglucose F 18 (FDG)-avid on PET scan PATIENT CHARACTERISTICS: * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * No previous allergic reaction to fludeoxyglucose F 18 * No contraindication to a pulmonary lobectomy and lymphadenectomy PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.